Mentors in Medicine Series on Applied Precision Medicine: Focus on Applying Precision Medicine to GI Cancers

Release Date: May 13, 2021
Expiration Date:  May 13, 2022

Activity Overview

Acknowledgement of Commercial Support

This activity is supported by educational grants from Janssen Scientific Affairs, LLC; Pharmacyclics LLC, an AbbVie Company; and Seagen Inc.

 

Target Audience

This educational program is intended for medical oncologists involved in the treatment of patients with GI malignancies. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of GI malignancies are also invited to attend.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC, have no relevant financial relationships with ineligible entities.

Series Chair

Andre H. Goy, MD
Physician-in-Chief, Hackensack Meridian Health Oncology Care Transformation Service
Chairman & Chief Physician Officer, John Theurer Cancer Center
Lydia Pfund Chair for Lymphoma
Academic Chairman Oncology, Hackensack Meridian School of Medicine
Professor of Medicine, Georgetown University
Hackensack, NJ

Disclosures:Grant/Research Support: PI: Acerta Pharma, AstraZeneca, Celgene Corporation, Constellation Pharmaceuticals, Genentech/Hoffmann-La Roche, Infinity Pharmaceuticals, Infinity Pharmaceuticals/Verastem Oncology, Janssen Pharmaceuticals, Karyopharm, Kite Pharma, Pharmacyclics; Consultant: Acerta Pharma, Celgene Corporation, Gilead Sciences, Janssen Pharmaceuticals, Kite Pharma, Xcenda; Stock/Shareholder: COTA; Other: Honoraria: AstraZeneca, Celgene Corporation, Gilead Sciences, Kite Pharma, Xcenda; Advisory: AstraZeneca, COTA, Elsevier’s PracticeUpdate, Gilead Sciences, Janssen Pharmaceuticals, Kite Pharma.

Moderator

Martin Gutierrez, MD
Director of Drug Discovery/Phase 1 Research
Co-Chief of Thoracic Oncology
John Theurer Cancer Center
Hackensack University Medical Center
Hackensack, NJ

Disclosures:Martin Gutierrez, MD has no relevant financial relationships with ineligible companies.

Faculty

Tanios Bekaii-Saab, MD, FACP
Professor, Mayo Clinic College of Medicine and Science
Leader, Gastrointestinal Cancer Program
Medical Director, Cancer Clinical Research Office
Vice Chair and Section Chief, Medical Oncology
Consortium Chair, ACCRU Research Network
Mayo Clinic
Phoenix, AZ

Disclosures:Research Funding (to institution): Agios, Arys, Arcus, Atreca, Boston Biomedical, Bayer, Amgen, Merck, Celgene, Lilly, Ipsen, Clovis, Seagen, Genentech, Novartis, Mirati, Merus, AbGenomics, Incyte, Pfizer, Bristol Myers Squibb; Consulting (to institution): Ipsen, Array Biopharma, Pfizer, Seagen, Bayer, Genentech, Incyte and Merck; Consulting (to self): AbbVie, Boehringer Ingelheim, Janssen, Eisai, Daiichi Sankyo, Natera, Treos Bio, Celularity, Exact Science, Sobi, BeiGene, Xilis, AstraZeneca and Foundation Medicine; IDMC/DSMB (to self): AstraZeneca, Exelixis, Lilly, PanCAN, and 1Globe; Scientific Advisory Board: Imugene, Immuneering, and Sun BioPharma; Inventions/Patents: WO/2018/183488 and WO/2019/055687.

John L. Marshall, MD
Chief, Division of Hematology/Oncology
Medstar Georgetown University Hospital
Director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer
Georgetown University Medical Center
Washington, DC

 

Disclosures:Consultant: Caris, Indivumed, Bayer, Taiho; Speakers’ Bureau: Taiho, Bayer, Merck, Pfizer, Daiichi Sankyo.

Zev Aryeh Wainberg, MD
Professor of Medicine
University of California
Los Angeles, CA

Disclosures:Grant/Research Support: Plexxikon, Arcus, Novartis; Consultant: Amgen, AstraZeneca, Daiichi Sankyo, Bayer, Bristol Myers Squibb, Merck, Ipsen, Five Prime, Gilead, Arcus, Astellas, Molecular Templates, Array, EMD Serono.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.